4-(4-phenyl-piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine | 252722-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-phenyl-piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 4-(4-phenylpiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
• CAS: 252722-59-1
• 化学式: C₁₇H₁₈N₄
• 分子量: 278.357
• InChiKey: GMUPYKQZMBLHEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：Pfizer inc.

  公开号：US20040058922A1

  公开（公告）日：2004-03-25

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  该化合物的化学式为1，其中R1、R2和R3如上所定义，是蛋白酪氨酸激酶的抑制剂，例如Janus Kinase 3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化症、类风湿性关节炎、银屑病、1型糖尿病及糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫性疾病的治疗。
• PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS
  申请人：Salas Solana Jorge

  公开号：US20100113420A1

  公开（公告）日：2010-05-06

  Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors.

  化合物式为（I）的吡咯吡咯啉衍生物可用作JAK3激酶抑制剂。
• PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1087971B1

  公开（公告）日：2004-07-07
• Kinase Modulators and Methods of Use
  申请人：Anand Neel K.

  公开号：US20080076774A1

  公开（公告）日：2008-03-27

  The present invention relates to compounds of the Formula (I) and (II) wherein R, R 21 , R 25 -R 33 , m, n, X 21 -X 23 , and Q 1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.
• US6635762B1
  申请人：——

  公开号：US6635762B1

  公开（公告）日：2003-10-21